The new class includes a diverse range of expertise including cancer biology, neuroscience, bioinformatics, psychiatry, cardiology, and more.
Please join us in welcoming our newest 2024 Class of AV Fellows. Selected from more than 300 applications, the 2024 class includes 11 leading PhD, MD, and postdoc candidates from world-renowned institutions globally, with a diverse range of backgrounds including cancer biology, neuroscience, bioinformatics, psychiatry, cardiology, and more. The class will work closely with our team to support all aspects of the investment process, from due diligence and deal sourcing to portfolio support.
The year-long program is an opportunity for students currently enrolled in a PhD or MD program (or postdoc/residency) to gain real-world experience by working directly with impactful healthcare startups from the ARTIS Ventures portfolio, learn about new cutting-edge TechBio technologies, and collaborate with other fellows and alumni as well as the broader AV Healthcare Pioneers network, an ecosystem of pharma and biotech execs, investors, regulators, LPs, and more.
“Since the inception of our Fellows Program in 2021, we have been increasingly impressed by our applicants, and every year we have had the difficult task of choosing an exceptional—and exceptionally small—group from a pool with hundreds of brilliant, qualified candidates,” said Vasudev Bailey, PhD, Managing Partner at ARTIS Ventures. “This year’s group includes 11 up-and-coming minds in science and health, and we are confident they will have a tremendous impact for ARTIS and our portfolio companies.”
Founded in 2001, ARTIS Ventures partners with entrepreneurs who are driven to positively impact their world through disruptive technological and scientific innovation, focusing on the intersection of computer science and life science, a convergence ARTIS calls TechBio.
For more information about the ARTIS Ventures Fellows Program or to sign-up for future information about upcoming programs and applications visit our fellows page. For more information about ARTIS Ventures, its team, and its portfolio, visit our homepage.